WO2014046441A1 - 돌라스타틴 10 유도체, 그의 제조방법 및 그를 포함하는 항암제 조성물 - Google Patents
돌라스타틴 10 유도체, 그의 제조방법 및 그를 포함하는 항암제 조성물 Download PDFInfo
- Publication number
- WO2014046441A1 WO2014046441A1 PCT/KR2013/008371 KR2013008371W WO2014046441A1 WO 2014046441 A1 WO2014046441 A1 WO 2014046441A1 KR 2013008371 W KR2013008371 W KR 2013008371W WO 2014046441 A1 WO2014046441 A1 WO 2014046441A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- methoxy
- amino
- oxoheptan
- compound
- Prior art date
Links
- KYZQYPHDDNCOQV-WMHUGKPPSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(C[C@@H](C1)OC)[C@@H]1[C@@H]([C@@H](C)C(NCC(c1c(C)cccc1)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(C[C@@H](C1)OC)[C@@H]1[C@@H]([C@@H](C)C(NCC(c1c(C)cccc1)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O KYZQYPHDDNCOQV-WMHUGKPPSA-N 0.000 description 1
- LGEKKADHFQVCEX-PHXBYCTMSA-N C[C@H]([C@H]([C@H](C[C@H](C1)OC)N1C(OC(C)(C)C)=O)OC)C(NCC(c1ccccc1)=O)=O Chemical compound C[C@H]([C@H]([C@H](C[C@H](C1)OC)N1C(OC(C)(C)C)=O)OC)C(NCC(c1ccccc1)=O)=O LGEKKADHFQVCEX-PHXBYCTMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a dolastatin 10 derivative having excellent anticancer activity, a preparation method thereof, and an anticancer composition comprising the same as an active ingredient.
- Dolastatin 10 was isolated from the Indian Ocean marine life Dolabella auricularia in 1987 and was identified as having the following chemical structure [J. Am. Chem. Soc., 1987, 109, 6883-6885.
- the bioactivity of dolastatin 10 is a tubulin inhibitor such as taxane and vinca alkaloid, but is a structurally different peptide [Chem. Ind., 1999, 51-55; Curr. Pharm. Des., 1999, 5, 139-162.
- Dolastatin 10 showed activity against various human tumors in cell and animal model experiments in preclinical studies. This was expected to be small. However, despite the structural differences, dolastatin 10 showed myelotoxicity, neurotoxicity and other side effects like taxane and vinca alkaloids in clinical trials [Clin. Cancer Res., 2000, 6, 1293-1301; Drugs of the Future, 1999, 24 (4), 404-409].
- dolastatin 10 Various derivatives of dolastatin 10 have been synthesized and the synthesis studies have been carried out in five parts: Dov (dollavaline), Val (valine), Dolaisoleucine, Dolaproline and Dolaamine. . Among them, the dolaproline and dolaamine moieties were the main research subjects. International publication WO 2003/008378 discloses a dolastatin 10 derivative in which the methoxy group of the dolaproline moiety is replaced with a thiomethoxy group, and US Patent No. 5,599,902. Dolstatin 10 derivatives with modified amine moieties have been reported. EP 2 260 858 also discloses derivatives in which the dimethylvaline of the Dov moiety is replaced with monomethylvaline.
- the present inventors have studied diligently to develop dolastatin 10 derivatives having more potent cytotoxicity against cancer cells. It was discovered that the present invention has been completed.
- Another object of the present invention is to provide a method for preparing a dolastatin 10 derivative of formula (I) or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide an anticancer agent composition containing a dolastatin 10 derivative of formula (I) or a pharmaceutically acceptable salt thereof.
- the present invention relates to a dolastatin 10 derivative of formula (I) or a pharmaceutically acceptable salt thereof:
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently hydrogen or an alkyl group of C 1 -C 4 ,
- Ar is an aryl group
- X is carbon, oxygen or sulfur
- R 7 Hydroxy, amino, C when X is carbon One -C 4 Alkoxy group, C One -C 4 of Alkylamino group or oxo ( ⁇ O) and is absent when X is oxygen or sulfur.
- an alkyl group of C 1 -C 4 means a straight or branched hydrocarbon having 1 to 4 carbon atoms, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl t-butyl, and the like, but is not limited thereto.
- the aryl group herein includes both an aromatic group and a heteroaromatic group and partially reduced derivatives thereof.
- the aromatic group is a simple or fused cyclic consisting of 5 to 15 pentagons
- heteroaromatic group refers to an aromatic group containing one or more oxygen, sulfur or nitrogen.
- Examples of representative aryl groups include phenyl, naphthyl, pyridinyl, furanyl, thiophenyl, indolyl, quinolinyl, imidazolinyl, Oxazolyl, thiazolyl, tetrahydronaphthyl, and the like, but are not limited thereto.
- a C 1 -C 4 alkoxy group refers to a straight or branched alkoxy group composed of 1 to 4 carbon atoms, and includes, but is not limited to, methoxy, ethoxy, n-propaneoxy and the like.
- One -C 4 of Alkylamino group is C One -C 4 Means an amino group substituted with an alkyl group, and includes, but is not limited to, methylamino, ethylamino, n-propylamino and the like.
- C One -C 4 Alkyl group, aryl group, C One -C 4 Alkoxy group and C One -C 4 of Alkylamino groups contain one or more hydrogen atoms One -C 4 Alkyl group, C 2 -C 4 Alkenyl, C 2 -C 4 Alkynyl, C 3 -C 10 Cycloalkyl group, C One -C 4 Haloalkyl group, C One -C 4 Alkoxy group, C One -C 4 Thioalkoxy, aryl, acyl, hydroxy, thio, halogen, amino, alkoxycarbonyl, carboxy, carbamoyl, cyano, nitro and the like.
- the dolastatin 10 derivative of the present invention is the dolastatin 10 derivative of the present invention.
- R 1 , R 3 and R 4 are alkyl groups of C 1 -C 4 ,
- R 2 and R 5 are each independently hydrogen or an alkyl group of C 1 -C 4 ,
- Ar is phenyl optionally substituted with one or more substituents selected from the group consisting of an alkoxy group and a halogen alkyl group of C 1 -C 4, C 1 -C 4 ,
- X is carbon
- R 7 Silver hydroxy, amino, C One -C 4 Alkoxy group or C One -C 4 of Alkylamino group.
- the dolastatin 10 derivative of the present invention More preferably, the dolastatin 10 derivative of the present invention
- R 1 , R 3 and R 4 are methyl
- R 2 and R 5 are each independently hydrogen or methyl
- Ar is phenyl unsubstituted or substituted with one or more substituents selected from the group consisting of methyl, methoxy and halogen,
- X is carbon
- R 7 is hydroxy, amino, methoxy or N-methylamino.
- the dolastatin 10 derivative of the present invention includes all stereoisomers and may be a compound of formula (Ia).
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Ar, X and R 7 are as defined in Formula I above.
- R 5 , R 6 and R 7 may each independently be (R) -type, (S) -type or racemic type.
- compositions herein include both non-toxic inorganic and organic acid salts, including but not limited to hydrochloride, sulfate, nitrate, phosphate, acetate, benzenesulfonate, citrate, and the like. It is not.
- Representative compounds of the dolastatin 10 derivatives of the present invention may be selected from the following groups.
- the present invention relates to a method for preparing a dolastatin 10 derivative of the formula (I), the method of the present invention is condensation reaction of the compound of formula II and the compound of formula (III), and then deprotected if a protecting group is present Gelatinization reaction.
- R 1 and R 2 are each independently hydrogen, an alkyl group or an amino protecting group of C 1 -C 4 ,
- R 3 , R 4 and R 5 are each independently hydrogen or an alkyl group of C 1 -C 4 ,
- Ar is an aryl group
- X is carbon, oxygen or sulfur
- R 7 Is a protected or unprotected hydroxy, an unprotected amino when C is carbon, C One -C 4 Alkoxy groups, protected or not C One -C 4 of Alkylamino group or oxo ( ⁇ O) and is absent when X is oxygen or sulfur.
- amino protecting group examples include t-butoxycarbonyl (t-Boc), carbenzyloxy (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), benzyl (Bn), and the like, but are not limited thereto. .
- hydroxy protecting group t-butyldimethylsilyl may be used, but the present invention is not limited thereto.
- the compound of Formula III may be used in the form of a salt, including but not limited to hydrochloride, trifluoroacetic acid (TFA) salt, and the like.
- a salt including but not limited to hydrochloride, trifluoroacetic acid (TFA) salt, and the like.
- the condensation reaction may be carried out in the presence of a condensing agent, and as the condensing agent, dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), diethyl cyanophosphonate (DEPC), benzotriazole -1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate (BOP reagent) and the like can be used, but not limited thereto.
- a condensing agent dicyclohexylcarbodiimide (DCC), diphenylphosphoryl azide (DPPA), diethyl cyanophosphonate (DEPC), benzotriazole -1-yl-oxy-tris (dimethylamino) phosphonium hexafluorophosphate (BOP reagent) and the like can be used, but not limited thereto.
- DCC dicyclohexylcarbodiimide
- DPPA
- an organic base such as triethylamine or diisopropylethylamine (DIPEA) can be used with the condensing agent.
- DIPEA diisopropylethylamine
- Halogenated aliphatic hydrocarbons such as chloroform and dichloromethane, ethyl acetate, tetrahydrofuran (THF), dimethylformamide (DMF), acetonitrile, etc. may be used as the reaction solvent, and the reaction temperature is preferably 0 to 50 ° C, More preferably, it is 0 degreeC-normal temperature.
- the deprotection reaction of the amino protecting group can be carried out using 10% palladium carbon or 20% palladium hydroxide.
- the deprotection reaction of the hydroxy protecting group can be carried out using tetrabutylammonium fluoride.
- the compound of Formula III is a known method [Tetrahedron, Vol. 49, No. 9, pp. 1913-1924 can be prepared according to Scheme I below.
- the methods described in the following reaction schemes are merely illustrative of the methods used, and the order of unit operations, reaction reagents, reaction conditions, and the like may be changed as much as the case may be.
- R 4 and R 5 are each independently hydrogen or an alkyl group of C 1 -C 4 ,
- Ar is an aryl group
- X is carbon, oxygen or sulfur
- R 7 Is a protected or unprotected hydroxy, an unprotected amino when C is carbon, C One -C 4 Alkoxy groups, protected or not C One -C 4 of Alkylamino group or oxo ( ⁇ O) and is absent when X is oxygen or sulfur,
- R 8 is an alkyl group of C 1 -C 4 .
- a compound of Formula VI is synthesized by adding dibutylboron triplate with triethylamine and Lewis acid as a base to a compound of Formula IV and a compound of Formula V.
- the stereochemistry of the compound of formula VI can be adjusted according to the order of addition of base and Lewis acid.
- Condensation reaction of the obtained compound of formula VIII with a compound of formula IX can synthesize a compound of formula X.
- the compound of Formula IX may be used in the form of a salt, including but not limited to hydrochloride, trifluoroacetic acid (TFA) salt, and the like.
- the condensation reaction can be carried out using the same reagents and conditions as the condensation reaction of the compound of formula II with the compound of formula III.
- the amino protecting group of the compound of formula X is then deprotected with hydrochloric acid or trifluoroacetic acid to prepare a compound of formula III.
- the dolastatin 10 derivative of the present invention shows excellent antitumor activity (see Test Example 1).
- the present invention relates to an anticancer agent, in particular a breast cancer agent, comprising the dolastatin 10 derivative of formula (I) or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
- the anticancer agent according to the present invention may be administered orally (eg, by taking or inhaling) or parenterally (eg by injection, deposition, transplantation, suppository), and the injection may be, for example, intravenous, subcutaneous. Injection, intramuscular injection or intraperitoneal injection.
- the anticancer agent according to the present invention is formulated into tablets, capsules, granules, fine subtilae, powders, sublingual tablets, suppositories, ointments, injections, emulsions, suspensions, syrups, sprays and the like depending on the route of administration. Can be.
- the anticancer agent according to the various forms of the present invention can be prepared by a known technique using a pharmaceutically acceptable carrier commonly used in each formulation.
- Examples of pharmaceutically acceptable carriers include excipients, binders, disintegrating agents, lubricants, preservatives, antioxidants, isotonic agents, buffers, coatings, sweeteners, solubilizers, bases, dispersants, wetting agents , Suspending agents, stabilizers, coloring agents and the like.
- the anticancer agent according to the present invention varies depending on the form of the medicament, but includes about 0.01 to 95% by weight of the compound of the present invention or a pharmaceutically acceptable salt thereof.
- the specific dosage of the anticancer agent of the present invention may vary depending on the type of mammal including the person to be treated, weight, sex, degree of disease, and judgment of a doctor.
- a doctor Preferably, in the case of oral administration, 0.01 to 50 mg of active ingredient per kg of body weight per day is administered, and in the case of parenteral administration, 0.01 to 10 mg of active ingredient per kg of body weight per day are administered.
- the total daily dose may be administered at one time or divided into several times depending on the extent of the disease, the judgment of the doctor.
- the dolastatin 10 derivative of the present invention is a novel synthetic compound, and may be usefully used to treat tumors, slow tumor growth, and prevent an increase in the number of tumors. For example, it is effective for inhibiting or preventing tumor growth in premalignant and malignant cells, and for forming carcinoma-forming solid tumors, especially colon cancer, lung cancer, breast cancer, gastric cancer, cervical cancer, bladder cancer, etc. It is useful for the treatment of blood cancer as well as solid cancer.
- Nt-butoxycarbonyl-L-prolinol (2 g, 9.9 mmol) was dissolved in 12 mL of dimethylsulfoxide, and the temperature was lowered to 5-10 ° C., triethylamine (4.8 mL, 34.7 mmol) was added and the mixture was stirred at 5 ⁇ 10 ° C. for 15 minutes. Sulfur trioxide-pyridine complex (5.5 g, 34.7 mmol) was added to the resulting reaction solution at 0 ° C. and stirred for 2 hours.
- reaction mixture was filtered through celite, the solvent was removed under reduced pressure, and the residue was extracted by adding ether and water to the residue and washed with brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed to give the title compound as a dark yellow oil.
- the concentrated residue was dissolved in 100 ml of methanol under an argon stream, benzaldehyde (1.07 ml, 10.6 mmol) was added thereto, stirred at 20-25 ° C. for 1 hour, and sodium cyano borohydride (0.67 g, 10.6 mmol) was added thereto. Stir for 16 hours. Paraformaldehyde (0.91g, 10.1mmol) was added to the reaction solution, and after stirring for 2 hours, when completely dissolved, sodium cyanoborohydride (0.67g, 10.6mmol) was added thereto and stirred for 4 hours.
- Example 1 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-((2,6-difluorophenethyl) ) Amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptan-4-yl)- N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-1)
- Example 7 (2S) -N-((3R, 4S) -3-methoxy-1-((2S, 4R) -4-methoxy-2-((1R, 2R) -1-methoxy- 2-Methyl-3-oxo-3-(((S) -1-oxo-1-phenylpropan-2-yl) amino) propyl) pyrrolidin-1-yl) -5-methyl-1-oxoheptane -4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-7)
- Example 8 (S) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N-((3R, 4S, 5S) -1-((2R, 4R)- 4-hydroxy-2-((1R, 2R) -1-methoxy-2-methyl-3-oxo-3- (phenethylamino) propyl) pyrrolidin-1-yl) -3-methoxy- 5-methyl-1-oxoheptan-4-yl) -N, 3-dimethylbutanamide (I-8)
- Example 10 (S) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N-((3R, 4S, 5S) -3-methoxy-1-(( 2R, 4S) -4-methoxy-2-((1R, 2R) -1-methoxy-2-methyl-3-oxo-3- (phenethylamino) propyl) pyrrolidin-1-yl)- 5-methyl-1-oxoheptan-4-yl) -N, 3-dimethylbutanamide (I-10)
- Example 11 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-(((R) -1- (4-) Fluorophenyl) -1-oxopropan-2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5 -Methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-11)
- Example 12 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-(((S) -1- (4- Fluorophenyl) -1-oxopropan-2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5 -Methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-12)
- Example 13 (S) -N-((3R, 4S, 5S) -3-methoxy-1-((2R, 4R) -4-methoxy-2-((1R, 2R) -1-meth Methoxy-3-(((R) -1- (2-methoxyphenyl) -1-oxopropan-2-yl) amino) -2-methyl-3-oxopropyl) pyrrolidin-1-yl)- 5-Methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-13)
- Example 14 (S) -N-((3R, 4S, 5S) -3-methoxy-1-((2R, 4R) -4-methoxy-2-((1R, 2R) -1-methoxy Methoxy-3-(((R) -1- (3-methoxyphenyl) -1-oxopropan-2-yl) amino) -2-methyl-3-oxopropyl) pyrrolidin-1-yl)- 5-Methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-14)
- Example 15 (S) -N-((3R, 4S, 5S) -3-methoxy-1-((2R, 4R) -4-methoxy-2-((1R, 2R) -1-meth Methoxy-3-(((R) -1- (4-methoxyphenyl) -1-oxopropan-2-yl) amino) -2-methyl-3-oxopropyl) pyrrolidin-1-yl)- 5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-15)
- Example 16 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-(((S) -1- (3, 5-difluorophenyl) -1-oxopropan-2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-meth Toxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-16)
- Example 17 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-(((S) -1- (2, 6-difluorophenyl) -1-oxopropan-2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-meth Toxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-17)
- Example 18 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-(((R) -1- (2, 6-difluorophenyl) -1-oxopropan-2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-meth Toxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-18)
- Example 19 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-(((R, Z) -1--1- ( Hydroxyimino) -1- (3-methoxyphenyl) propan-2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl)- 3-methoxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I -19)
- Example 20 (S) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N-((3R, 4S, 5S) -1-((2R, 4R)- 2-((1R, 2R) -3-(((R) -1- (hydroxyimino) -1- (3-methoxyphenyl) propan-2-yl) amino) -1-methoxy-2- Methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethylbutanamide (I-20 )
- Example 21 (S) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N-((3R, 4S, 5S) -1-((2R, 4R)- 2-((1R, 2R) -3-(((R) -1- (4-fluorophenyl) -1- (hydroxyimino) propan-2-yl) amino) -1-methoxy-2- Methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethylbutanamide (I-21 )
- Example 22 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-((2- (5-bromo-2) -Methylphenyl) -2- (hydroxyimino) ethyl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5- Methyl-1-oxoheptan-4-yl) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N, 3-dimethylbutanamide (I-22)
- Example 23 (S) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N-((3R, 4S, 5S) -1-((2R, 4R)- 2-((1R, 2R) -3-((2- (4-fluoro-2-methylphenyl) -2- (hydroxyimino) ethyl) amino) -1-methoxy-2-methyl-3-oxo Propyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethylbutanamide (I-23)
- Example 24 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-((2- (4-fluoro-2) -Methylphenyl) -2- (hydroxyimino) ethyl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5- Methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-24)
- Example 25 (S) -N-((3R, 4S, 5S) -1-((2S, 4R) -2-((1R, 2R) -3-(((E) -2- (2- Fluoro-4-methoxyphenyl) -2-hydroxyimino) ethyl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3- Methoxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-25 )
- Example 26 (S) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N-((3R, 4S, 5S) -1-((2R, 4R)- 2-((1R, 2R) -3-((2- (4-fluoro-2-methylphenyl) -2- (oxoethyl) amino) -1-methoxy-2-methyl-3-oxopropyl)- 4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethylbutanamide (I-26)
- Example 27 (S) -N-((3R, 4S, 5S) -1-((2R, 4R) -2-((1R, 2R) -3-((2- (4-fluoro-2) -Methylphenyl) -2- (oxoethyl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1 -Oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-27)
- Example 28 (S) -N-((3R, 4S, 5S) -3-methoxy-1-((2S, 4R) -4-methoxy-2-((1R, 2R) -1-meth Methoxy-2-methyl-3-oxo-3-((2-oxo-2- (o-tolyl) ethyl) amino) propyl) pyrrolidin-1-yl) -5-methyl-1-oxoheptan-4 -Yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-28)
- Example 29 (S) -N-((3R, 4S, 5S) -3-methoxy-1-((2S, 4R) -4-methoxy-2-((1R, 2R) -1-meth Methoxy-2-methyl-3-oxo-3-((2-oxo-2- (p-tolyl) ethyl) amino) propyl) pyrrolidin-1-yl) -5-methyl-1-oxoheptan-4 -Yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-29)
- Example 30 (S) -N-((3R, 4S, 5S) -1-((2S, 4R) -2-((1R, 2R) -3- (2- (4-fluorophenyl)- 2-oxoethyl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptan-4 -Yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-30)
- Example 32 (S) -N-((3R, 4S, 5S) -1-((S) -4-((1R, 2R) -3-((2,6-difluorophenethyl) amino ) -1-methoxy-2-methyl-3-oxopropyl) thiazolidin-3-yl) -3-methoxy-5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl- 2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-32)
- Example 34 (2S) -N-((3R, 4S) -3-methoxy-1-((2S, 4R) -4-methoxy-2-((1R, 2R) -1-methoxy- 2-methyl-3-oxo-3-((2-oxo-2-phenylethyl) amino) propyl) pyrrolidin-1-yl) -5-methyl-1-oxoheptan-4-yl) -N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-34)
- Example 36 (2S) -N-((3R, 4S) -1-((2S) -2-((1R, 2R) -3-(((2R) -1-amino-1-phenylpropane-) 2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptan-4- Yl) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N, 3-dimethylbutanamide (I-36)
- Example 37 (2S) -N-((3R, 4S) -1-((2S, 4R) -2-((1R, 2R) -3-(((2S) -1-amino-1-phenyl Propane-2-yl) amino) -1-methoxy-2-methyl-3-oxopropyl) -4-methoxypyrrolidin-1-yl) -3-methoxy-5-methyl-1-oxoheptane- 4-yl) -2-((S) -2- (dimethylamino) -3-methylbutanamido) -N, 3-dimethylbutanamide (I-37)
- Example 38 (2S) -N-((3R, 4S) -3-methoxy-1-((2S, 4R) -4-methoxy-2-((1R, 2R) -1-methoxy- 2-methyl-3-oxo-3-((2- (pyridin-2-yl) ethyl) amino) propyl) pyrrolidin-1-yl) -5-methyl-1-oxoheptan-4-yl)- N, 3-dimethyl-2-((S) -3-methyl-2- (methylamino) butanamido) butanamide (I-38)
- the amino group of the title compound (I-38) was obtained in the same manner as in Example 1, using the compound (VII-15) obtained in Preparation Example 6-15 instead of the compound (VII-1) obtained in Preparation Example 6-1. 0.35 g (35%) of protected compound was obtained.
- the amino group of the title compound (I-39) was obtained in the same manner as in Example 1, using the compound (VII-16) obtained in Preparation Example 6-16 instead of the compound (VII-1) obtained in Preparation Example 6-1. 0.8 g (99%) of the protected compound was obtained.
- the azide compound of Compound (I-44) was dissolved in 10 mL of methyl alcohol, 10% palladium carbon (15 mg) was added, and stirred for 14 hours under a hydrogen atmosphere. At the end of the reaction, the reaction mixture was filtered through celite, washed several times with methanol, and the solvent was removed under reduced pressure to yield 0.23 g (99%) of the title compound as a white solid.
- breast cancer (BT-474), skin epithelial cancer (A-431), non-small cell lung cancer (NCI-H460), colon cancer (HT-29), colon cancer (SW-620), breast cancer (MDA-MB- 231) and breast cancer (MCF-7) were used to perform antitumor activity assays.
- a single suspension of tumor cells was serially diluted and seeded in a 96-well microtestplate.
- the microtestplates were then incubated at 37 ° C. for 4 days in a 5% CO 2 environment (2-3 ⁇ 10 3 cells / well).
- Cell growth in monolayers was measured using WST-8 (Dojindo, Japan).
- the IC 50 value of the drug against tumor cells was calculated as the concentration of drug representing 50% OD of control growth. The results are shown in Table 1 below.
Abstract
Description
Claims (14)
- 제1항에 있어서,R1, R3 및 R4가 C1-C4의 알킬기이고,R2 및 R5가 각각 독립적으로 수소 또는 C1-C4의 알킬기이며,R6는 수소, 히드록시, C1-C4의 알콕시기, 아미노, 옥소(=O) 또는 히드록시이미노(=N-OH)이고,Ar은 C1-C4의 알킬기, C1-C4의 알콕시기 및 할로겐으로 구성된 군으로부터 선택된 하나 이상의 치환기로 치환되거나 치환되지 않은 페닐이며,X는 탄소이고,R7은 히드록시, 아미노, C1-C4의 알콕시기 또는 C1-C4의 알킬아미노기인 것을 특징으로 하는 돌라스타틴 10 유도체 또는 그의 약제학적으로 허용되는 염.
- 제1항에 있어서,R1, R3 및 R4가 메틸이고,R2 및 R5가 각각 독립적으로 수소 또는 메틸이며,R6는 수소, 히드록시, 메톡시, 아미노, 옥소(=O) 또는 히드록시이미노(=N-OH)이고,Ar은 메틸, 메톡시 및 할로겐으로 구성된 군으로부터 선택된 하나 이상의 치환기로 치환되거나 치환되지 않은 페닐이며,X는 탄소이고,R7은 히드록시, 아미노, 메톡시 또는 N-메틸아미노인 것을 특징으로 하는 돌라스타틴 10 유도체 또는 그의 약제학적으로 허용되는 염.
- 제1항에 있어서, 하기 화합물로부터 선택되는 것을 특징으로 하는 돌라스타틴 10 유도체 또는 그의 약제학적으로 허용되는 염:(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2,6-디플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-1);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((3-플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-2);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((4-플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-3);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2,4-디클로로-5-플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-4);(2S)-N-((3R,4S)-3-메톡시-1-((2R,4R)-4-메톡시-2-((1R,2R)-1-메톡시-3-((2-(4-메톡시페닐)-2-옥소에틸)아미노)-2-메틸-3-옥소프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-5);(2S)-N-((3R,4S)-3-메톡시-1-((2R,4R)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-(((R)-1-옥소-1-페닐프로판-2-일)아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-6);(2S)-N-((3R,4S)-3-메톡시-1-((2S,4R)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-(((S)-1-옥소-1-페닐프로판-2-일)아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-7);(S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S,5S)-1-((2R,4R)-4-히드록시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-(페네틸아미노)프로필)피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (Ⅰ-8);(S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S,5S)-3-메톡시-1-((R)-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-(페네틸아미노)프로필)-4-옥소피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (Ⅰ-9);(S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S,5S)-3-메톡시-1-((2R,4S)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-(페네틸아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (Ⅰ-10);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((R)-1-(4-플루오로페닐)-1-옥소프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-11);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((S)-1-(4-플루오로페닐)-1-옥소프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-12);(S)-N-((3R,4S,5S)-3-메톡시-1-((2R,4R)-4-메톡시-2-((1R,2R)-1-메톡시-3-(((R)-1-(2-메톡시페닐)-1-옥소프로판-2-일)아미노)-2-메틸-3-옥소프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-13);(S)-N-((3R,4S,5S)-3-메톡시-1-((2R,4R)-4-메톡시-2-((1R,2R)-1-메톡시-3-(((R)-1-(3-메톡시페닐)-1-옥소프로판-2-일)아미노)-2-메틸-3-옥소프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-14);(S)-N-((3R,4S,5S)-3-메톡시-1-((2R,4R)-4-메톡시-2-((1R,2R)-1-메톡시-3-(((R)-1-(4-메톡시페닐)-1-옥소프로판-2-일)아미노)-2-메틸-3-옥소프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-15);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((S)-1-(3,5-디플루오로페닐)-1-옥소프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-16);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((S)-1-(2,6-디플루오로페닐)-1-옥소프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-17);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((R)-1-(2,6-디플루오로페닐)-1-옥소프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-18);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((R,Z)-1-(히드록시이미노)-1-(3-메톡시페닐)프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-19);(S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((R)-1-(히드록시이미노)-1-(3-메톡시페닐)프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (Ⅰ-20);(S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-(((R)-1-(4-플루오로페닐)-1-(히드록시이미노)프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (Ⅰ-21);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2-(5-브로모-2-메틸페닐)-2-(히드록시이미노)에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N,3-디메틸부탄아미드 (Ⅰ-22);(S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2-(4-플루오로-2-메틸페닐)-2-(히드록시이미노)에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (Ⅰ-23);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2-(4-플루오로-2-메틸페닐)-2-(히드록시이미노)에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-24);(S)-N-((3R,4S,5S)-1-((2S,4R)-2-((1R,2R)-3-(((E)-2-(2-플루오로-4-메톡시페닐)-2-히드록시이미노)에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-25);(S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2-(4-플루오로-2-메틸페닐)-2-(옥소에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (Ⅰ-26);(S)-N-((3R,4S,5S)-1-((2R,4R)-2-((1R,2R)-3-((2-(4-플루오로-2-메틸페닐)-2-(옥소에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-27);(S)-N-((3R,4S,5S)-3-메톡시-1-((2S,4R)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-((2-옥소-2-(o-톨릴)에틸)아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-28);(S)-N-((3R,4S,5S)-3-메톡시-1-((2S,4R)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-((2-옥소-2-(p-톨릴)에틸)아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-29);(S)-N-((3R,4S,5S)-1-((2S,4R)-2-((1R,2R)-3-(2-(4-플루오로페닐)-2-옥소에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-30);(S)-N-((3R,4S,5S)-1-((2S,4R)-2-((1R,2R)-3-(2-(2-플루오로-4-메톡시페닐)-2-옥소에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-31);(S)-N-((3R,4S,5S)-1-((S)-4-((1R,2R)-3-((2,6-디플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)티아졸리딘-3-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-32);(2S)-N-((3R,4S)-3-메톡시-1-((2S,4S)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-(페네틸아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-33);(2S)-N-((3R,4S)-3-메톡시-1-((2S,4R)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-((2-옥소-2-페닐에틸)아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-34);(2S)-N-((3R,4S)-1-((2S,4R)-2-((1R,2R)-3-(2-(2-히드록시-2-페닐에틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-35);(2S)-N-((3R,4S)-1-((2S)-2-((1R,2R)-3-(((2R)-1-아미노-1-페닐프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N,3-디메틸부탄아미드 (Ⅰ-36);(2S)-N-((3R,4S)-1-((2S,4R)-2-((1R,2R)-3-(((2S)-1-아미노-1-페닐프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-메톡시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N,3-디메틸부탄아미드 (Ⅰ-37);(2S)-N-((3R,4S)-3-메톡시-1-((2S,4R)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-((2-(피리딘-2-일)에틸)아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-38);(2S)-N-((3R,4S)-3-메톡시-1-((2S,4R)-4-메톡시-2-((1R,2R)-1-메톡시-2-메틸-3-옥소-3-((2-(티오펜-2-일)에틸)아미노)프로필)피롤리딘-1-일)-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (Ⅰ-39);(2S)-N-((3R,4S)-1-((2S,4S)-2-((1R,2R)-3-((2,6-디플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-히드록시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N,3-디메틸부탄아미드 (I-40);(2S)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N-((3R,4S)-1-((2S,4S)-2-((1R,2R)-3-(((S)-1-(4-플루오로페닐)-1-옥소프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-히드록시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸부탄아미드 (I-41);(2S)-N-((3R,4S)-1-((2S,4S)-2-((1R,2R)-3-((2,6-디플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-히드록시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (I-42);(2S)-N-((3R,4S)-1-((2S,4S)-2-((1R,2R)-3-(((S)-1-(4-플루오로페닐)-1-옥소프로판-2-일)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-히드록시피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-N,3-디메틸-2-((S)-3-메틸-2-(메틸아미노)부탄아미도)부탄아미드 (I-43);(2S)-N-((3R,4S)-1-((2S,4S)-4-아미노-2-((1R,2R)-3-((2,6-디플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N,3-디메틸부탄아미드 (I-44); 및(2S)-N-((3R,4S)-1-((2S,4S)-2-((1R,2R)-3-((2,6-디플루오로페네틸)아미노)-1-메톡시-2-메틸-3-옥소프로필)-4-(메틸아미노)피롤리딘-1-일)-3-메톡시-5-메틸-1-옥소헵탄-4-일)-2-((S)-2-(디메틸아미노)-3-메틸부탄아미도)-N,3-디메틸부탄아미드 (I-45).
- 하기 화학식 II의 화합물과 하기 화학식 III의 화합물을 축합반응시킨 다음, 보호기가 존재하는 경우 탈보호화 반응시키는 단계를 포함하는 하기 화학식 I의 돌라스타틴 10 유도체의 제조방법:[화학식 II][화학식 III][화학식 I]상기 식에서,R1 및 R2는 각각 독립적으로 수소, C1-C4의 알킬기 또는 아미노 보호기이고,R3, R4 및 R5는 각각 독립적으로 수소 또는 C1-C4의 알킬기이며,R6는 수소, 보호화되거나 되지 않은 히드록시, C1-C4의 알콕시기, 보호화되거나 되지 않은 아미노, 옥소(=O) 또는 히드록시이미노(=N-OH)이고,Ar은 아릴기이며,X는 탄소, 산소 또는 황이고,R7은 X가 탄소일 때 보호화되거나 되지 않은 히드록시, 보호화되거나 되지 않은 아미노, C1-C4의 알콕시기, 보호화되거나 되지 않은 C1-C4의 알킬아미노기 또는 옥소(=O)이고, X가 산소 또는 황일 때 존재하지 않는다.
- 제6항에 있어서, 아미노 보호기가 t-부톡시카르보닐(t-Boc), 카르보벤질옥시(Cbz), 9-플루오레닐메톡시카르보닐(Fmoc) 또는 벤질(Bn)인 것을 특징으로 하는 제조방법.
- 제6항에 있어서, 히드록시 보호기가 t-부틸디메틸실릴인 것을 특징으로 하는 제조방법.
- 제6항에 있어서, 화학식 III의 화합물이 염산염 또는 트리플루오로아세트산(TFA)염의 형태로 사용되는 것을 특징으로 하는 제조방법.
- 제6항에 있어서, 축합반응이 디시클로헥실카르보디이미드(DCC), 디페닐포스포릴아지드(DPPA), 디에틸 시아노포스포네이트(DEPC) 및 벤조트리아졸-1-일-옥시-트리스(디메틸아미노)포스포늄헥사플루오로포스페이트(BOP 시약)로 구성된 군으로부터 선택된 축합제와 트리에틸아민 및 디이소프로필에틸아민(DIPEA)으로 구성된 군으로부터 선택된 유기 염기의 존재 하에 수행되는 것을 특징으로 하는 제조방법.
- 제6항에 있어서, 아미노 보호기의 탈보호화 반응이 10% 팔라듐 카본 또는 20% 수산화팔라듐을 사용하여 수행되는 것을 특징으로 하는 제조방법.
- 제6항에 있어서, 히드록시 보호기의 탈보호화 반응이 테트라부틸암모늄 플루오라이드를 사용하여 수행되는 것을 특징으로 하는 제조방법.
- 제1항 내지 제5항 중 어느 한 항에 따른 돌라스타틴 10 유도체 또는 그의 약제학적으로 허용되는 염을 약제학적으로 허용가능한 담체와 함께 포함하는 항암제 조성물.
- 제13항에 있어서, 항암제가 유방암 치료에 적용되는 것을 특징으로 항암제 조성물.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES13839929.0T ES2604766T3 (es) | 2012-09-20 | 2013-09-16 | Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo |
CA2885973A CA2885973C (en) | 2012-09-20 | 2013-09-16 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same |
US14/430,059 US9278996B2 (en) | 2012-09-20 | 2013-09-16 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same |
JP2015532955A JP6089108B2 (ja) | 2012-09-20 | 2013-09-16 | ドラスタチン10誘導体、その製造方法およびそれを含む抗癌剤組成物 |
AU2013318779A AU2013318779B2 (en) | 2012-09-20 | 2013-09-16 | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same |
EP13839929.0A EP2889287B1 (en) | 2012-09-20 | 2013-09-16 | Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same |
CN201380048896.4A CN104640842B (zh) | 2012-09-20 | 2013-09-16 | 海兔毒素-10衍生物、其制法及包含其的抗癌药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0104710 | 2012-09-20 | ||
KR20120104710 | 2012-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014046441A1 true WO2014046441A1 (ko) | 2014-03-27 |
Family
ID=50341676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/008371 WO2014046441A1 (ko) | 2012-09-20 | 2013-09-16 | 돌라스타틴 10 유도체, 그의 제조방법 및 그를 포함하는 항암제 조성물 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9278996B2 (ko) |
EP (1) | EP2889287B1 (ko) |
JP (1) | JP6089108B2 (ko) |
KR (1) | KR101520302B1 (ko) |
AU (1) | AU2013318779B2 (ko) |
CA (1) | CA2885973C (ko) |
ES (1) | ES2604766T3 (ko) |
WO (1) | WO2014046441A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018042303A1 (en) | 2016-08-29 | 2018-03-08 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
WO2018209735A1 (zh) * | 2017-05-19 | 2018-11-22 | 中国科学院过程工程研究所 | 一种丙烯酸酯的低温液相制备方法 |
US11453677B2 (en) | 2016-03-08 | 2022-09-27 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US11629149B2 (en) | 2018-02-28 | 2023-04-18 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013318779B2 (en) | 2012-09-20 | 2016-07-28 | Celltrion, Inc. | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same |
WO2019094709A1 (en) * | 2017-11-09 | 2019-05-16 | Pettit George R | Betulastatin compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260858A2 (en) | 1986-09-19 | 1988-03-23 | Canon Kabushiki Kaisha | Photoelectric conversion apparatus |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5654399A (en) | 1991-08-09 | 1997-08-05 | Teikoku Hormone Mfg. Co., Ltd. | Tetrapeptide derivative having antitumor activity |
WO2003008378A1 (en) | 2001-07-19 | 2003-01-30 | F.Hoffmann-La Roche Ag | Dolastatin 10 derivatives |
US6569834B1 (en) * | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
AU2013318779B2 (en) | 2012-09-20 | 2016-07-28 | Celltrion, Inc. | Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same |
-
2013
- 2013-09-16 AU AU2013318779A patent/AU2013318779B2/en not_active Ceased
- 2013-09-16 CA CA2885973A patent/CA2885973C/en not_active Expired - Fee Related
- 2013-09-16 ES ES13839929.0T patent/ES2604766T3/es active Active
- 2013-09-16 US US14/430,059 patent/US9278996B2/en active Active
- 2013-09-16 JP JP2015532955A patent/JP6089108B2/ja not_active Expired - Fee Related
- 2013-09-16 WO PCT/KR2013/008371 patent/WO2014046441A1/ko active Application Filing
- 2013-09-16 EP EP13839929.0A patent/EP2889287B1/en not_active Not-in-force
- 2013-09-16 KR KR1020130111137A patent/KR101520302B1/ko active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260858A2 (en) | 1986-09-19 | 1988-03-23 | Canon Kabushiki Kaisha | Photoelectric conversion apparatus |
US5654399A (en) | 1991-08-09 | 1997-08-05 | Teikoku Hormone Mfg. Co., Ltd. | Tetrapeptide derivative having antitumor activity |
US6004934A (en) * | 1991-08-09 | 1999-12-21 | Teikoku Hormone Mfg. Co., Ltd. | Tetrapeptide derivative |
US6569834B1 (en) * | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
WO2003008378A1 (en) | 2001-07-19 | 2003-01-30 | F.Hoffmann-La Roche Ag | Dolastatin 10 derivatives |
Non-Patent Citations (10)
Title |
---|
CHEM. IND., 1999, pages 51 - 55 |
CLIN. CANCER RES., vol. 6, 2000, pages 1293 - 1301 |
CURR. PHARM. DES., vol. 5, 1999, pages 139 - 162 |
DRUGS OF THE FUTURE, vol. 24, no. 4, 1999, pages 404 - 409 |
J. AM. CHEM. SOC., vol. 109, 1987, pages 6883 - 6885 |
NABUYUKI YAMAMOTO ET AL.: "Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks", CANCER SCIENCE, vol. 100, no. 2, 2009, pages 316 - 321, XP055182335 * |
See also references of EP2889287A4 * |
STEVEN D. SHNYDER ET AL.: "Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 31, 2007, pages 353 - 360, XP055182334 * |
TETRAHEDRON LETTERS, vol. 32, no. 21, pages 2395 - 2398 |
TETRAHEDRON, vol. 49, no. 9, pages 1913 - 1924 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11453677B2 (en) | 2016-03-08 | 2022-09-27 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
WO2018042303A1 (en) | 2016-08-29 | 2018-03-08 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
EP3848372A1 (en) | 2016-08-29 | 2021-07-14 | Novartis AG | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
US11098051B2 (en) | 2016-08-29 | 2021-08-24 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
US11912715B2 (en) | 2016-08-29 | 2024-02-27 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
WO2018209735A1 (zh) * | 2017-05-19 | 2018-11-22 | 中国科学院过程工程研究所 | 一种丙烯酸酯的低温液相制备方法 |
US11629149B2 (en) | 2018-02-28 | 2023-04-18 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
ES2604766T3 (es) | 2017-03-09 |
EP2889287B1 (en) | 2016-08-31 |
KR101520302B1 (ko) | 2015-05-15 |
AU2013318779A1 (en) | 2015-04-09 |
CA2885973A1 (en) | 2014-03-27 |
JP6089108B2 (ja) | 2017-03-01 |
US20150225455A1 (en) | 2015-08-13 |
US9278996B2 (en) | 2016-03-08 |
CA2885973C (en) | 2017-09-05 |
EP2889287A1 (en) | 2015-07-01 |
EP2889287A4 (en) | 2015-08-19 |
KR20140038324A (ko) | 2014-03-28 |
CN104640842A (zh) | 2015-05-20 |
AU2013318779B2 (en) | 2016-07-28 |
JP2015530403A (ja) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014046441A1 (ko) | 돌라스타틴 10 유도체, 그의 제조방법 및 그를 포함하는 항암제 조성물 | |
WO2014107024A1 (ko) | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 | |
WO2018182341A1 (ko) | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 | |
WO2011043568A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2021187886A1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
WO2010056022A2 (en) | Melanocortin receptor agonists | |
WO2016064082A2 (ko) | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 | |
WO2019078522A1 (ko) | 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2018066872A1 (ko) | 3-페닐-2,3,4,8,9,10-헥사히드로피라노[2,3-f]크로멘 유도체 및 이의 광학 이성질체 합성 방법 | |
WO2013048164A1 (en) | NOVEL COMPOUNDS AS HIF-1αINHIBITORS AND MANUFACTURING PROCESS THEREOF | |
WO2014109530A1 (ko) | 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2016032209A2 (ko) | 야누스인산화효소 억제제로서의 치환된 n-(피롤리딘-3-일)-7h-피롤로[2,3-d]피리미딘-4-아민 | |
WO2018226053A1 (ko) | 시클로프로필아민 유도체 화합물 및 이의 용도 | |
WO2020242204A1 (ko) | Jak 저해제 화합물, 및 이를 포함하는 의약 조성물 | |
WO2017034245A1 (ko) | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 | |
EP2331529A2 (en) | Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof | |
WO2021086069A1 (ko) | Ezh2 저해제 및 e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2009093872A2 (ko) | 신규한 디아민 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 암 치료용 약학 조성물 | |
WO2012134188A2 (ko) | 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 | |
WO2020141923A2 (ko) | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 | |
WO2023018237A1 (en) | Novel plk1 degradation inducing compound | |
WO2021194228A1 (ko) | 암의 예방 또는 치료용 약학적 조성물 | |
WO2017150903A1 (en) | Sulfamate derivative compounds, processes for preparing them and their uses | |
WO2009148291A2 (en) | 3- or 4-substituted piperidine compounds | |
WO2021086038A1 (ko) | 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13839929 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2885973 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015532955 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14430059 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2013839929 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013839929 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013318779 Country of ref document: AU Date of ref document: 20130916 Kind code of ref document: A |